Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada

Journal of Medical Economics

Volumn 15, Issue SUPPL. 1, 2012, Pages 3-14

  Chau, D ^a   Becker, D L ^b   Coombes, M E ^b   Ioannidis, G ^c   Adachi, J D ^c   Goeree, R ^c,d  

^a Amgen Canada Inc   (Canada)

^b Health Economics and Outcomes Research   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d PATH Research Institute   (Canada)

Author keywords

Canada; Cost effectiveness; Denosumab; Fracture; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; GENERIC DRUG; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; SPINE FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; ETIDRONIC ACID; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; ONTARIO; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS;

EID: 84869407844     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.737393     Document Type: Article

References (61)

1. Ioannidis G, Papaioannou A, Hopman W, et al. Relation between fractures and mortality: results from the Canadian multicentre osteoporosis study. CMAJ 2009;181:265-71
2. Papaioannou A, Wiktorowicz ME, Adachi JD, et al. Mortality, independence in living, and refracture one year following hip fracture in Canadians. J Soc Obstet Gynaecol Can 2000;22:591-7
3. Cooper C, Atkinson EJ, O'Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992;7:221-7
4. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-21
5. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61
6. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
7. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38-42
8. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73
9. Melo M, Qiu F, Sykora K, et al. Persistence with bisphosphonate therapy in older people. J Am Geriatr Soc 2006;54:1015-6
10. Blouin J, Dragomir A, Ste-Marie LG, et al. Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab 2007;92:887-94
11. Jones TJ, Petrella RJ, Crilly R. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 2008;35:1865-73
12. Sampalis JS, Adachi JD, Rampakakis E, et al. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 2012;27(1):202-10
13. Sheehy O, Kindundu C, Barbeau M, et al. Differences in persistence among different weekly oral bisphosponate medications. Osteoporos Int 2009; 20:1583-94
14. Murthy RK, Morrow PK, Theriault RL. Bone biology and the role of the RANK ligand pathway. Oncology (Williston Park) 2009;23:9-15
15. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
16. Prolia(R) (denosumab) Product Monograph. Submission Control Number 149015. Toronto: Amgen Canada Inc, 2011. http://webprod3.hc-sc.gc.ca/dpd-bdpp/ info.do?langeng&code82897. Accessed December 24, 2011
17. Freemantle N, Satram-Hoang S, Tang E, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23(1):317-26
18. Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011; 22:967-82
19. Strom O, Borgstrom F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007;18:1047-61
20. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 2000;11:120-7
21. De Laet C, van Hout BA, Burger H, et al. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997;315: 221-5
22. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401-9
23. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34
24. Goeree R, Blackhouse G, Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin 2006;22:1425-36
25. Coyle D, Cranney A, Lee KM, et al. Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 2001;19:565-75
26. Coyle D, Hadj Tahar A, Murphy G, et al. Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis. Canadian Agency for Drugs and Technologies in Health 200670
27. Consumer Price Index. Health and personal care, by province (Canada). Ottawa: Statistics Canada, 2011. http://www40.statcan.gc.ca/l01/cst01/econ161a- eng.htm. Accessed December 6, 2011
28. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edn. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006
29. Ministry of Health. Ontario Drug Benefit Formulary/Comparative Drug Index. Ontario: Ontario Drug Benefit Program, 2010. http://www.health.gov.on.ca/ english/providers/program/drugs/odbf-eformulary.html. Accessed May 13, 2010
30. Stevenson M, Davis S. Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. NICE, University of Sheffield, 2006. http://www.nice.org.uk/guidance/index.jsp?actiondownload&rtrue&o36717. Accessed March 3, 2009
31. McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012;27:211-8
32. HUInc. Summary Statistics for HUI-Reference Scores of Health-Related Quality of Life. Health Utilities Inc, 2006. http://www.healthutilities.com/24- HUI3Can-F20-85.pdf. Accessed December 14, 2011
33. Peasgood T, Herrmann K, Kanis JA, et al. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 2009;20(6):853-68
34. Black DM, Cummings SR, Stone K, et al. A new approach to defining normal vertebral dimensions. J Bone Miner Res 1991;6:883-92
35. Adachi JD, Hanley DA, Lorrain J, et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresporptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Therapeut 2007;29:2055-67
36. NICE. Systematic reviews of clinical effectiveness prepared for the guideline "Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk". United Kingdom: NICE, 2008. http://www.nice.org.uk/guidance/index.jsp?actiondownload&o42362. Accessed March 17, 2011
37. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
38. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
39. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
40. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727-36
41. Boonen S, McClung MR, Minisola S, et al. Effect of denosumab on the incidence of hip, new vertebral, and nonvertebral fractures over 3 years among postmenopausal women with higher fracture risk: a subgroup analysis from the FREEDOM study. J Bone Miner Res 2009;24(S1):S60, abstract number 1199
42. Inderjeeth CA, Foo AC, Lai MM, et al. Efficacy and safety of pharmacological agents in managing osteoporosis in the old: review of the evidence. Bone 2009;44:744-51
43. Schachter HM, Clifford TH, Cranney A, et al. Raloxifene for primary and secondary prevention of osteoporotic fractures in postmenopausal women: a systematic review of efficacy and safety evidence. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2005. Report No.: 50
44. Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporosis Int 2000;11:680-7
45. Leslie WD, Sadatsafavi M, Lix LM, et al. Secular decreases in fracture rates 1986-2006 for Manitoba, Canada: a population-based anlaysis. Osteoporos Int 2011;22:2137-43
46. Gaudette LA, Silberberger C, Altmayer CA, et al. Trends in breast cancer incidence and mortality. Health Rep 1996;8:29-37
47. Barrett JA, Baron JA, Beach ML. Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Int 2003;14:889-94
48. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2009. Toronto: Canadian Cancer Society, 2009. www.cancer.ca/statist. Accessed December 10, 2009
49. Life Tables, Canada, Provinces and Territories. 2000 to 2002. Ottawa: Statistics Canada, 2006. http://www.statcan.gc.ca/bsolc/olc-cel/olc-cel? langeng&catno84-537-X. Accessed February 24, 2009
50. Kanis JA, Adams J, Borgstrom F, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008;42:4-15
51. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468-73
52. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;15:108-12
53. Metge C, Azimaee M, Lix LM, et al. Using cost-of-illness analysis to describe the direct cost burden of fracture: Estimates of potential savings from prevention. The Canadian Association for Population Therapeutics Annual Conference, Toronto, Ontario, March 28-30, 2010
54. Schedule of Benefits for Physician Services under the Health Insurance Act. Ontario Ministry of Health and Long-term Care, 2008. http://www.health.gov. on.ca/english/providers/program/ohip/sob/physserv/physserv-mn.html. Accessed March 4, 2010
55. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004;52:1832-9
56. Morin S, Lix LM, Azimaee M, et al. Institutionalization following incident nontraumatic fractures in community-dwelling men and women. Osteoporosis Int 2012;23(9):2381-6
57. Hutton JM, Brown R, Borowitz M. A new decision model for cost-utility comparison of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996;9(2 Suppl):8-22
58. Zethraeus N, Johannesson M, Jonsson B. A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 1999;15:352-65
59. Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 2005;16:15-25
60. Groeneveld PW, Lieu TA, Fendrick AM, et al. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol 2001;96:338-47
61. Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004;30:549-56